EL7.AI
StocksUpdated•Originally published 6 July 2026•Updated 6 July 2026•
1 min read

HSBC Hikes AbbVie Price Target to $300 Amid Mixed Analyst Adjustments

Key Facts

1Cantor Fitzgerald raised AbbVie's (ABBV) price target to $265 while maintaining an Overweight rating.
2JP Morgan raised Citizens Financial Group's (CFG) price target to $76.00 despite GuruFocus data suggesting overvaluation.
3BMO Capital significantly lowered Dow Inc's (DOW) price target from $46.00 to $33.00.

As analysts recalibrate investment portfolios within the immunology and financial sectors, HSBC has issued a notably bullish outlook for AbbVie (ABBV), raising its price target to $300 with a Buy rating. This follows Cantor Fitzgerald's target increase to $265 for the same stock, while JP Morgan raised its target for Citizens Financial Group (CFG) to $76.00. Conversely, BMO Capital significantly lowered its price target for Dow Inc from $46.00 to $33.00 due to fluctuating market conditions.

These adjustments occur as pharmaceutical peers like Amgen (AMGN) show relative stability, with its stock closing at $374.15 per market data on July 2, 2026. Compared to previous quarter results, researchers are attempting to pin down fair value for healthcare firms amid pricing pressures, while the regional banking sector remains under scrutiny for net interest margins. Experts suggest the downgrade for Dow Inc reflects broader concerns regarding global industrial demand and raw material costs.

Regarding current price levels, ABBV closed at $261.07 and CFG at $70.98 (as of July 2, 2026). Investors should watch for upcoming macroeconomic data, including manufacturing PMI reports which could further impact basic materials stocks, as well as any regulatory updates affecting the biotechnology and pharmaceutical sectors.